Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
QuiaPEG Pharmaceuticals AB
AB
Active
Org 5566946140
Virdings Allé 32 B, 754 50
Uppsala
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2005 · 20 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
QuiaPEG Pharmaceuticals AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
2M
2M
1M
1M
0M
2020: 2M
2M
2020
2021: 0M (-100% vs 2020)
0M
-100%
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
EBITDA
SEK millions
0M
-6M
-12M
-19M
-25M
2020: -20M
-20M
2020
2021: -13M (+35% vs 2020)
-13M
+35%
2021
2022: -10M (+23% vs 2021)
-10M
+23%
2022
2023: -9M (+10% vs 2022)
-9M
+10%
2023
2024: -6M (+33% vs 2023)
-6M
+33%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
0
0
0
216
1 861
Staff expenses
—
—
—
—
—
EBITDA
−5 963
−9 129
−10 138
−12 519
−19 938
Depreciation & amort.
−3 952
−3 859
−3 368
−2 201
−1 267
EBIT
−9 915
−12 988
−13 506
−14 720
−21 205
Net financials
−32
−25
−55
−182
−741
Profit before tax
−9 947
−13 013
−13 561
−14 902
−21 946
Tax
−0
−0
−0
−0
−0
Net profit
−9 947
−13 013
−13 561
−14 902
−21 946
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
16 998
20 936
21 518
18 687
15 016
Equity
12 408
16 155
5 748
1 209
911
Long-term debt
0
0
56
370
1 148
Short-term debt
4 590
4 781
15 714
17 108
12 957
Total debt
4 590
4 781
15 770
17 478
14 105
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
73,0 %
This company
38,2 %
Market median
This company
Market median
91% above market
2020
2024
Return on equity
−80,2 %
This company
18,4 %
Market median
This company
Market median
536% below market
2020
2024
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2020
2024
Debt / equity
0,37×
This company
0,62×
Market median
This company
Market median
40% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on QuiaPEG Pharmaceuticals AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
